buy

Alnylam Pharmace. buy Royal Bank of Canada

Alnylam Pharmace.

Start price

€137.40

/ 50%

Target price

20.02.25

Performance (%)

Price

Summary

This prediction is currently active. The BUY prediction by Royal_Bank_of_Canada for Alnylam Pharmace. is nearly unchanged. This prediction currently runs until 20.02.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

Feedback

Performance without dividends (%)

Name	1w	1m
Alnylam Pharmace.
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by Royal_Bank_of_Canada for this prediction

In the thread Alnylam Pharmace. diskutieren

Prediction Buy

Perf. (%)

Target price 217.070

Change

Ends at

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $235.00 price target on the stock.

Ratings data for ALNY provided by MarketBeat

Royal Bank of Canada